Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
February 16 2022 - 7:30AM
Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology, today announced two upcoming presentations on the
OTO-413 hearing loss program at the 49th Annual Scientific and
Technology Meeting of the American Auditory Society (AAS) to be
held February 24-26, 2022 in Scottsdale, Arizona. These include a
podium presentation of previously disclosed results from the
OTO-413 Phase 1/2 clinical trial and a general review of the
OTO-413 program as an invited presentation in a special session on
hearing therapeutics. Details of these presentations are as
follows:
Podium Presentation Title: Neurotrophin OTO-413
for hearing loss: Phase 1/2 clinical studyDate and
Time: February 24, 2022 from 4:00-4:20 p.m.
MSTPresenter: David R. Moore, Ph.D., Director,
Communication Sciences Research Center at Cincinnati Children’s
Hospital Medical Center, and Professor of Otolaryngology and
Neuroscience at the University of Cincinnati College of
Medicine
Invited Presentation Title: OTO-413:
intratympanic BDNF for the treatment of hearing lossSpecial
Session Title: The Future of Hearing
TherapeuticsDate and Time: February 26, 2022 from
1:30-4:00 p.m. MSTPresenter: Alan C. Foster,
Ph.D., Chief Scientific Officer of Otonomy
About OtonomyOtonomy is a biopharmaceutical
company dedicated to the development of innovative therapeutics for
neurotology. The company pioneered the application of drug delivery
technology to the ear in order to develop products that achieve
sustained drug exposure from a single local administration. This
approach is covered by a broad patent estate and is being utilized
to develop a pipeline of products addressing important unmet
medical needs with a focus on hearing loss and tinnitus. For
additional information please visit www.otonomy.com.
Contacts:
Media Inquiries:Spectrum ScienceCate CullenAccount
Director205.910.4443ccullen@spectrumscience.com
Investor Inquiries:Westwicke ICRRobert H. UhlManaging
Director858.356.5932robert.uhl@westwicke.com
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From May 2024 to Jun 2024
Otonomy (NASDAQ:OTIC)
Historical Stock Chart
From Jun 2023 to Jun 2024